Literature DB >> 32300806

Cost of Hospitalization Associated With Respiratory Syncytial Virus Infection Versus Influenza Infection in Hospitalized Older Adults.

Bradley Ackerson1, Jaejin An1, Lina S Sy1, Zendi Solano1, Jeff Slezak1, Hung-Fu Tseng1.   

Abstract

Despite the severity of respiratory syncytial virus (RSV) disease in older adults, data on its costs are limited. We compared hospitalization costs for 2090 adults aged ≥ 60 years hospitalized with RSV or influenza by assigning direct health care costs. Hospitalization with RSV was associated with longer hospitalization and increased frequency of diagnosis-related groups for pulmonary complications, resulting in costs at least as great as those for influenza ($16 034 vs $15 163; 95% confidence interval for the difference, -$811 to $2547). Awareness of RSV disease burden in adults is needed to facilitate vaccination and treatment when they become available.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  respiratory syncytial virus; adult; cost; hospitalization; influenza

Year:  2020        PMID: 32300806     DOI: 10.1093/infdis/jiaa183

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  The Importance of AGO 1 and 4 in Post-Transcriptional Gene Regulatory Function of tRF5-GluCTC, an Respiratory Syncytial Virus-Induced tRNA-Derived RNA Fragment.

Authors:  Eun-Jin Choi; Junping Ren; Ke Zhang; Wenzhe Wu; Yong Sun Lee; Inhan Lee; Xiaoyong Bao
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

2.  Summarizing Study Characteristics and Diagnostic Performance of Commercially Available Tests for Respiratory Syncytial Virus: A Scoping Literature Review in the COVID-19 Era.

Authors:  David I Bernstein; Asuncion Mejias; Barbara Rath; Christopher W Woods; Jamie Phillips Deeter
Journal:  J Appl Lab Med       Date:  2022-07-20

3.  Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study.

Authors:  Jessica Hartnett; Prina Donga; Gabriela Ispas; Yannick Vandendijck; David Anderson; Stacey House; Selim Suner
Journal:  Influenza Other Respir Viruses       Date:  2022-04-26       Impact factor: 5.606

Review 4.  Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population.

Authors:  Laura M Stephens; Steven M Varga
Journal:  Vaccines (Basel)       Date:  2021-06-09

5.  Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017-2019.

Authors:  Yoonyoung Choi; Alexandra Hill-Ricciuti; Angela R Branche; William D Sieling; Lisa Saiman; Edward E Walsh; Matthew Phillips; Ann R Falsey; Lyn Finelli
Journal:  Influenza Other Respir Viruses       Date:  2021-10-03       Impact factor: 4.380

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.